{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:21:14Z","timestamp":1775820074657,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Loss of nuclear BAP1 (BRCA1-associated protein 1) expression is a well-established adverse prognostic marker in uveal melanoma (UM). However, data from Central and Southeastern European populations are limited. This descriptive study aimed to evaluate BAP1 immunohistochemical expression in a Croatian enucleation-based UM cohort, characterize its associations with clinicopathological parameters, and contextualize the findings within the published literature. Methods: Formalin-fixed, paraffin-embedded tumor tissue from 58 consecutive patients with primary choroidal and ciliary body melanoma treated with enucleation at University Hospital Centre Zagreb (2006\u20132016) was analyzed immunohistochemically for BAP1 nuclear expression. Associations with clinicopathological parameters were assessed using chi-square and Fisher\u2019s exact tests. Survival analysis was performed using Kaplan\u2013Meier estimation, log-rank tests, and Cox proportional hazards regression with a median follow-up of 11.2 years. Results: Loss of nuclear BAP1 expression was observed in 53\/58 (91.4%) specimens, resulting in a severely imbalanced distribution (53 versus 5 patients) precluding meaningful comparative survival analysis. Five-year and 10-year overall survival rates were 72.4% and 51.7%, respectively, with a median overall survival of 14.5 years. BAP1 loss was associated with longer disease-free survival (log-rank p = 0.020); however, this finding likely reflects a statistical artifact attributable to the extremely small BAP1-retained group (n = 5) harboring concurrent adverse features and should not be interpreted biologically. The study was underpowered to draw prognostic inferences regarding BAP1 status. Exploratory survival analyses are presented for transparency but should not be interpreted inferentially. Conclusions: The exceptionally high prevalence of BAP1 loss reflects the selection bias inherent in enucleation-based cohorts, which are enriched for large, molecularly high-risk tumors. This study provides the first comprehensive BAP1 immunohistochemical data from Croatia, contributing to the growing evidence that enucleation cohorts represent a distinct, biologically high-risk subgroup in which BAP1 immunohistochemistry offers limited discriminatory value. The extended follow-up of 11.2 years confirms the prolonged natural history of UM. Future multi-center studies incorporating molecular validation and diverse treatment modalities are needed to establish the prognostic utility of BAP1 across the full spectrum of UM disease.<\/jats:p>","DOI":"10.3390\/cancers18081211","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:20:16Z","timestamp":1775816416000},"page":"1211","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Characteristics and BAP1 Expression in an Enucleation-Based Uveal Melanoma Cohort: A Single-Center Croatian Experience with Long-Term Follow-Up"],"prefix":"10.3390","volume":"18","author":[{"given":"Domagoj","family":"Vla\u0161i\u0107","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Dubrovnik General Hospital, 20000 Dubrovnik, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Kne\u017ei\u0107 Zagorec","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital \u201cSveti Duh\u201d, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Jakov\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology \u201cLjudevit Jurak\u201d, University Hospital Centre \u201cSestre milosrdnice\u201d, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Le\u0161in Ga\u0107ina","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7887-4101","authenticated-orcid":false,"given":"Marijana","family":"\u0106ori\u0107","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomislav","family":"Juki\u0107","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: Epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2006). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch. Ophthalmol., 124, 1684\u20131693.","DOI":"10.1001\/archopht.124.12.1684"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: Results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"eaax1738","DOI":"10.1126\/sciadv.aax1738","article-title":"BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages, giving rise to BAP1-mutant cancers","volume":"5","author":"Kuznetsov","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/bjc.2014.417","article-title":"Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing","volume":"111","author":"Kalirai","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/modpathol.2014.43","article-title":"Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma","volume":"27","author":"Koopmans","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000502550","article-title":"BAP1 immunoreactivity correlates with gene expression class in uveal melanoma","volume":"6","author":"See","year":"2020","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cjp2.86","article-title":"Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma","volume":"4","author":"Farquhar","year":"2017","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"St\u00e5lhammar, G., See, T.R.O., Phillips, S., and Grossniklaus, H.E. (2021). Intratumor heterogeneity in uveal melanoma BAP-1 expression. Cancers, 13.","DOI":"10.3390\/cancers13051143"},{"key":"ref_16","first-page":"502","article-title":"Density of PAS positive patterns in uveal melanoma: Correlation with vasculogenic mimicry, gene expression class, BAP-1 expression, macrophage infiltration, and risk for metastasis","volume":"25","author":"See","year":"2019","journal-title":"Mol. Vis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/PAS.0000000000002176","article-title":"Prognostic value of BAP1 protein expression in uveal melanoma","volume":"48","author":"Kennedy","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11322","DOI":"10.1038\/s41467-025-66428-x","article-title":"Early genetic evolution of driver mutations in uveal melanoma","volume":"16","author":"Dollar","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_19","first-page":"257","article-title":"Clinico-epidemiological analysis of choroidal melanoma in Split Area, Croatia","volume":"65","year":"2011","journal-title":"Acta Med. Croat."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pa\u0161ali\u0107, D., Niku\u0161eva-Marti\u0107, T., Sekovani\u0107, A., and Ka\u0161telan, S. (2023). Genetic and epigenetic features of uveal melanoma\u2014An overview and clinical implications. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612807"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2559.2004.01874.x","article-title":"A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma","volume":"45","author":"Mudhar","year":"2004","journal-title":"Histopathology"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Liu-Smith, F., and Lu, Y. (2020). Opposite roles of BAP1 in overall survival of uveal melanoma and cutaneous melanoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020411"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8923","DOI":"10.1038\/s41598-021-88390-6","article-title":"Estimation of the timing of BAP1 mutation in uveal melanoma progression","volume":"11","author":"Uner","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1167\/iovs.13-12195","article-title":"Genomic profile of 320 uveal melanoma cases: Chromosome 8p-loss and metastatic outcome","volume":"54","author":"Ewens","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.4103\/ijo.IJO_313_21","article-title":"Ten-year outcomes of uveal melanoma based on The Cancer Genome Atlas (TCGA) classification in 1001 cases","volume":"69","author":"Shields","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"(1998). The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: Initial mortality findings. COMS report no. 10. Am. J. Ophthalmol., 125, 779\u2013796.","DOI":"10.1016\/S0002-9394(98)00039-7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/ijo.2021.5190","article-title":"Current molecular and clinical insights into uveal melanoma (Review)","volume":"58","author":"Fallico","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.modpat.2022.100081","article-title":"Prognostic value of BAP1 and preferentially expressed antigen in melanoma (PRAME) immunohistochemistry in uveal melanomas","volume":"36","author":"Han","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_29","first-page":"186","article-title":"Uveal Melanoma Treatment and Prognostication","volume":"6","author":"Jager","year":"2017","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41416-022-02133-6","article-title":"A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma","volume":"128","author":"Carlino","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41698-021-00226-8","article-title":"BAP1 methylation: A prognostic marker of uveal melanoma metastasis","volume":"5","author":"Bakhoum","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1541-7786.MCR-20-0434","article-title":"Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma","volume":"19","author":"Kuznetsoff","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1211\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:31:26Z","timestamp":1775817086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/8\/1211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["cancers18081211"],"URL":"https:\/\/doi.org\/10.3390\/cancers18081211","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}